OBM Transplantation is an international peer-reviewed Open Access journal, which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.
OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.
We welcome original clinical studies as well as basic science, reviews, short reports/rapid communications, case reports, opinions, technical notes, book reviews as well as letters to the editor.
Indexing: DOAJ-Directory of Open Access Journals.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 6 days from acceptance to publication (median values for papers published in this journal in the first half of 2020, 1-2 days of FREE language polishing time is also included in this period). A first decision provided to authors of manuscripts submitted to this journal are approximately 3.7 weeks (median values) after submission.
Lung and Heart Transplantation
Submission Deadline: November 15, 2020 (Open)
David J. Ross, MD
Medical / Scientific Consultant, LLC, USA; Medical Director, Transplant Molecular Diagnostics, CareDX, Inc. USA
Website | E-Mail
Research Interests: Lung transplantation; lung and heart transplantation; adult lung transplantation
About this topic
The field of cardiothoracic transplantation has experienced recent challenges mounting during the SARS-2 (CoVid-19) pandemic; nevertheless transplant volumes have since rebounded with a renewed sense of optimism and dedication. These experiences have highlighted the need for innovation with respect to modes of allograft surveillance, immunomodulation, and therapeutic strategies. Indeed, chronic allograft rejection remains an Achilles heel after solid organ transplantation which afflicts more than 50% of patients with chronic lung allograft dysfunction (CLAD) by 5-years after lung transplant, and cardiac allograft vasculopathy (CAV) by 10-years after heart transplantation .
Novel modes of pre-transplant mechanical circulatory device “bridging to transplantation” have experienced a renaissance, while protocols to expand donor organ availability for procurement have emerged, further enhancing post-transplant clinical outcomes.
In this special edition of OBM Transplantation, we invite authors for submission of articles which exemplify the spirit of innovation and creativity in this burgeoning cardiothoracic transplant field.
Chambers DC, Cherikh WS, Harhay MO, Hayes D, Hsich E, Khush KK, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: Donor and recipient size match. J Heart Lung Transplant. 2019; 38: 1042-1055.[CrossRef]
Dominic Emerson, Jon Kobashigawa, Ryan Levine, Jamie Moriguchi, Dominick Megna, Joshua Chung, Danny Ramzy, Alfredo Trento, Fardad Esmailian
Received: April 14, 2020; Published: July 06, 2020; doi:10.21926/obm.transplant.2003114